Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2001-04-17
2002-04-02
Jarvis, William R. A. (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
Reexamination Certificate
active
06365596
ABSTRACT:
The present invention relates to oral pharmaceutical compositions, in particular to compositions containing buprenorphin as active ingredient. These compositions are particularly stable with respect to the commercially available products.
BACKGROUND OF THE INVENTION
Buprenorphin, namely 21-cyclopropyl-7&agr;-(2-hydroxy-3,3-dimethyl-2butyl-)-6,14-endo-ethano-6,7,8,18-tetrahydroripavine, is a morphine alkaloid with analgesic properties. Its preparation is disclosed in U.S. Pat. No. 3,433,791, for a review see J. W. Lewis in Advan. Biochem. Psychopharmacol. Vol. 8, M. C. Braude et al. eds. (Raven Press, New York, 1974).
This analgesic is marketed under the trade marks TEMGESIC, BUPRENEX, LEPETAN.
Sublingual tablets containing buprenorphin as active ingredient, for example TEMGESIC 0.2 and 0.4 mg, show the presence of products from the degradation of the active ingredient.
DISCLOSURE OF THE INVENTION
It has now been found that the addition of pharmaceutically acceptable antioxidants gives oral pharmaceutical compositions, containing buprenorphin or a pharmaceutically acceptable salt thereof as active ingredient, a particularly good stability, decreasing the formation of the degradation products.
Advantageously, the oral pharmaceutical compositions according to the present invention are more stable than the presently available dosage forms of the state of the art, hence they have a longer shell-life.
Therefore, it is an object of the present invention an oral pharmaceutical composition containing buprenorphin or a pharmaceutically acceptable salt thereof as active ingredient characterised in that it contains a pharmaceutically acceptable antioxidant in addition to conventional vehicles and eccipients.
This and other objects of the present invention will be disclosed in detail, also by means of examples.
REFERENCES:
patent: 0 180 303 (1986-05-01), None
patent: WO97/33566 (1997-09-01), None
Farmaceutici Formenti S.p.A.
Jarvis William R. A.
Nixon & Vanderhye
LandOfFree
Oral pharmaceutical compositions containing buprenorphin does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Oral pharmaceutical compositions containing buprenorphin, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Oral pharmaceutical compositions containing buprenorphin will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2827780